Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug delivery from rapid gelling polymer composition

a technology of gelling polymer and polymer composition, which is applied in the direction of drug composition, aerosol delivery, cardiovascular disorders, etc., can solve the problems of adversely affecting tissue surfaces, worsening tissue inflammation at the site of administration,

Inactive Publication Date: 2009-07-30
ANGIOTECH INT AG (CH)
View PDF101 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides a biocompatible gel-forming drug-delivery composition for in vivo administration. The composition includes a drug, a first component with a sulfhydryl group, and a second component with a sulfhydryl reactive group. When the two components are mixed together, they form covalent bonds quickly to form a gel. The gel can be used to treat tissues by administering the composition to a tissue site and allowing the components to react with each other to form the gel. The gel has a gel time of less than one minute. The invention also provides a method for treating tissues by administering the composition and allowing the components to react with each other to form the gel. The composition can be administered in a liquid or powder form."

Problems solved by technology

One difficulty encountered when designing in situ hydrogel forming compositions is that optimizing the composition to enhance gel formation may worsen tissue inflammation at the site of administration.
A possible explanation for this effect is that highly reactive composition components that are capable of rapid gel formation may adversely affect tissue surfaces.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug delivery from rapid gelling polymer composition
  • Drug delivery from rapid gelling polymer composition
  • Drug delivery from rapid gelling polymer composition

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of a Two-Component Tissue Sealant Composition

[0374]a. First Component

[0375]Pentaerythritol poly(ethylene glycol)ether tetra-succinimidyl glutarate (“SG-PEG”) (mol. wt. 10,000) is dissolved in 0.5 mM sodium phosphate pH 6.0 at a concentration of 20% w / v. (This solution is not stable in aqueous media due to the susceptibility of the active ester to hydrolysis and should be used within one hour of preparation).

[0376]b. Second Component

[0377]Pentaerythritol poly(ethylene glycol)ether tetra-sulfhydryl (mol. wt. 10,000) is dissolved in 300 mM sodium phosphate / sodium carbonate buffer (“P / C buffer”), pH 9.6, at a concentration of 20% w / v. P / C buffer is prepared as follows: 300 mM sodium monobasic phosphate is mixed with 300 mM sodium carbonate to achieve pH 9.6. The final molarity is approximately 117 mm phosphate and 183 mM carbonate. This solution is stable in aqueous media, but care should be taken to prevent the exposure of the solution to oxygen to prevent oxidation to disu...

example 2

Surgical Sealing of Arteries

[0378]The right carotid artery of New Zealand white rabbits is exposed. The rabbits are treated with 200 U / kg of heparin and the vessel is clamped proximally and distally using atraumatic vascular clamps. A puncture hole is made in the carotid artery using a 27G needle. The control rabbits are treated with tamponade until hemostasis is achieved. For the treated rabbits, approximately 0.5 mL of each of the two components of the compositions prepared as described in Example 1 are delivered to the defect site using a two component sprayer (Duo Flow, Hemaedics, Malibu, Calif.). After the material is allowed to set for 30 sec, the clamps are removed and the time to hemostasis and the blood loss are measured. The arteries of the control rabbits also remain clamped for 30 sec for consistency. The results are shown in Table 1.

TABLE 1Blood Loss and Time to Hemostasis as a Function of TreatmentTreatmentBlood Loss (g)Time to Hemostasis (sec)Tamponade (n = 18)5.7 ± 3...

example 3

Surgical Sealing of an ePTFE Graft

[0380]The dogs are treated with heparin to achieve an activated clotting time of greater than 480 sec. The left iliac of the dogs is exposed and isolated using atraumatic vascular clamps placed distally and proximally. A 5 cm segment of the artery is excised and replaced with an ePTFE (polythetrafluoroethylene) graft of the same diameter. Prior to the completion of the anastamosis, the graft was de-aired using a 27G needle. Approximately 3.0 mL of each of the two components of the composition prepared according to Example 1 is delivered to the defect site using a two component sprayer (Cohesion Technologies, Inc., Palo Alto, Calif.). After the material is allowed to set for 30 sec, the clamps are removed and the time to hemostasis and the blood loss are measured. The procedure was repeated on the left iliac, with the exception of material application. The right iliac received only tamponade treatment. The results are shown in Table 2.

TABLE 2Blood Lo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
biocompatibleaaaaaaaaaa
hydrophobicaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 10 / 749,117, filed Dec. 30, 2003, now pending; which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 60 / 437,471, filed Dec. 30, 2002, and U.S. Provisional Patent Application No. 60 / 440,875, filed Jan. 17, 2003, which applications are included herein by reference in their entirety.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]This invention relates generally to compositions that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augment...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/337A61P35/00A61K9/06A61K47/34
CPCA61K9/0024A61K9/06A61L2300/434A61L31/16A61L31/145A61K9/1647A61K31/337A61K31/365A61K31/54A61K47/34A61L31/041C08L71/02C08L89/06A61K47/6903A61P35/00A61P43/00A61P7/04A61P9/00A61K51/1213
Inventor GRAVETT, DAVID M.TAKACS-COX, ANIKOTOLEIKIS, PHILIP M.MAITI, ARPITAEMBREE, LEANNE
Owner ANGIOTECH INT AG (CH)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com